In-depth genomic data analyses revealed complex transcriptional and epigenetic dysregulations of BRAFV600E in melanoma

BackgroundThe recurrent BRAF driver mutation V600E (BRAFV600E) is currently one of the most clinically relevant mutations in melanoma. However, the genome-wide transcriptional and epigenetic dysregulations induced by BRAFV600E are still unclear. The investigation of this driver mutation’s functional consequences is critical to the understanding of tumorigenesis and the development of therapeutic strategies.Methods and resultsWe performed an integrative analysis of transcriptomic and epigenomic changes disturbed by BRAFV600E by comparing the gene expression and methylation profiles of 34 primary cutaneous melanoma tumors harboring BRAFV600E with those of 27 BRAFWT samples available from The Cancer Genome Atlas (TCGA). A total of 711 significantly differentially expressed genes were identified as putative BRAFV600E target genes. Functional enrichment analyses revealed the transcription factor MITF (p < 3.6 × 10−16) and growth factor TGFB1 (p < 3.1 × 10−9) were the most significantly enriched up-regulators, with MITF being significantly up-regulated, whereas TGFB1 was significantly down-regulated in BRAFV600E, suggesting that they may mediate tumorigenesis driven by BRAFV600E. Further investigation using the MITF ChIP-Seq data confirmed that BRAFV600E led to an overall increased level of gene expression for the MITF targets. Furthermore, DNA methylation analysis revealed a global DNA methylation loss in BRAFV600E relative to BRAFWT. This might be due to BRAF dysregulation of DNMT3A, which was identified as a potential target with significant down-regulation in BRAFV600E. Finally, we demonstrated that BRAFV600E targets may play essential functional roles in cell growth and proliferation, measured by their effects on melanoma tumor growth using a short hairpin RNA silencing experimental dataset.ConclusionsOur integrative analysis identified a set of BRAFV600E target genes. Further analyses suggested a complex mechanism driven by mutation BRAFV600E on melanoma tumorigenesis that disturbs specific cancer-related genes, pathways, and methylation modifications.

[1]  J. Mesirov,et al.  Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer , 2011, Proceedings of the National Academy of Sciences.

[2]  Gordon K Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .

[3]  A. McKenna,et al.  The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. , 2014, Cancer discovery.

[4]  William Pao,et al.  Routine Multiplex Mutational Profiling of Melanomas Enables Enrollment in Genotype-Driven Therapeutic Trials , 2012, PloS one.

[5]  Jun S. Song,et al.  BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition , 2013, Proceedings of the National Academy of Sciences.

[6]  Editors-in-Chief C. Nicot.  Molecular Cancer , 2009 .

[7]  Kate Owen,et al.  Registered Report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation , 2016, eLife.

[8]  C. Bertolotto,et al.  Essential role of microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma , 2011, Oncogene.

[9]  Gerard C Blobe,et al.  Role of transforming growth factor Beta in human cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Helen Pickersgill,et al.  Oncogenic BRAF Regulates Melanoma Proliferation through the Lineage Specific Factor MITF , 2008, PloS one.

[11]  S. Michiels,et al.  Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas , 2008, Molecular oncology.

[12]  E. Tartour,et al.  Poems syndrome with high interleukin (IL)6 and IL1 beta serum levels, in a patient with thyroid carcinoma and melanoma. , 1994, European Journal of Cancer.

[13]  M. Dawson,et al.  Cancer Epigenetics: From Mechanism to Therapy , 2012, Cell.

[14]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[15]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[16]  T. Fennell,et al.  Melanoma genome sequencing reveals frequent PREX2 mutations , 2012, Nature.

[17]  G. Boivin,et al.  The aryl hydrocarbon receptor functions as a tumor suppressor of liver carcinogenesis. , 2010, Cancer research.

[18]  Dirk Schadendorf,et al.  Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .

[19]  D. Pinkel,et al.  Somatic activation of KIT in distinct subtypes of melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Middleton,et al.  Directed phenotype switching as an effective antimelanoma strategy. , 2013, Cancer cell.

[21]  J. Mesirov,et al.  A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. , 2014, Cancer discovery.

[22]  Wei Liu,et al.  Epidermal growth factor (EGF) and interleukin (IL)-1β synergistically promote ERK1/2-mediated invasive breast ductal cancer cell migration and invasion , 2012, Molecular Cancer.

[23]  R. Marais,et al.  Elevated expression of MITF counteracts B-RAF–stimulated melanocyte and melanoma cell proliferation , 2005, The Journal of cell biology.

[24]  L. Chin,et al.  The INK4a/ARF locus and melanoma , 2003, Oncogene.

[25]  A. Sivachenko,et al.  A Landscape of Driver Mutations in Melanoma , 2012, Cell.

[26]  Rafael A. Irizarry,et al.  Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays , 2014, Bioinform..

[27]  Rajiv Narayan,et al.  A melanocyte lineage program confers resistance to MAP kinase pathway inhibition , 2013, Nature.

[28]  M. Esteller,et al.  Cancer epigenomics: beyond genomics. , 2012, Current opinion in genetics & development.

[29]  M. van Engeland,et al.  Genetics and epigenetics of cutaneous malignant melanoma: a concert out of tune. , 2012, Biochimica et biophysica acta.

[30]  Xinming Wang,et al.  Role of aryl hydrocarbon receptor in cancer. , 2013, Biochimica et biophysica acta.

[31]  Su-Chun Zhang,et al.  Oncogenic BRAFV600E Induces Expression of Neuronal Differentiation Marker MAP2 in Melanoma Cells by Promoter Demethylation and Down-regulation of Transcription Repressor HES1* , 2009, The Journal of Biological Chemistry.

[32]  K. Sales,et al.  Seminal plasma induces the expression of IL-1α in normal and neoplastic cervical cells via EP2/EGFR/PI3K/AKT pathway , 2014, Journal of molecular signaling.

[33]  Junfeng Xia,et al.  Cancer Biology and Signal Transduction a Meta-analysis of Somatic Mutations from next Generation Sequencing of 241 Melanomas: a Road Map for the Study of Genes with Potential Clinical Relevance , 2022 .

[34]  S. Ariyan,et al.  Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032 , 2010, Journal of Translational Medicine.

[35]  K. Flaherty,et al.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.

[36]  P. Hou,et al.  The BRAFV600E causes widespread alterations in gene methylation in the genome of melanoma cells , 2012, Cell cycle.

[37]  D. Fan,et al.  Antitumor effects of liposomal IL1α and TNFα against the pulmonary metastases of the B16F10 murine melanoma in syngeneic mice , 1995, Clinical & Experimental Metastasis.

[38]  T. Golub,et al.  Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma , 2005, Nature.

[39]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[40]  C. Rodríguez-Cerdeira,et al.  New Perspectives of “omics” Applications in Melanoma Research , 2011, The open biochemistry journal.

[41]  D. Fan,et al.  Antitumor effects of liposomal IL1 alpha and TNF alpha against the pulmonary metastases of the B16F10 murine melanoma in syngeneic mice. , 1995, Clinical & experimental metastasis.

[42]  K. Flaherty,et al.  Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.

[43]  G. A. Limb,et al.  IL-1β Upregulates IL-8 Production in Human Müller Cells Through Activation of the p38 MAPK and ERK1/2 Signaling Pathways , 2014, Inflammation.

[44]  G. Perdew,et al.  Evidence for an Aryl Hydrocarbon Receptor-Mediated Cytochrome P450 Autoregulatory Pathway , 2007, Molecular Pharmacology.

[45]  A. Lasfar,et al.  Resistance to transforming growth factor β-mediated tumor suppression in melanoma: are multiple mechanisms in place? , 2010, Carcinogenesis.

[46]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[47]  J. Fridlyand,et al.  Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.

[48]  Dennie T. Frederick,et al.  Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma , 2012, Clinical Cancer Research.

[49]  K. Matsuzaki,et al.  Down-regulation of TGF-β receptors in human colorectal cancer: implications for cancer development , 1999, British Journal of Cancer.

[50]  Ximing J. Yang,et al.  TGF-β Regulates DNA Methyltransferase Expression in Prostate Cancer, Correlates with Aggressive Capabilities, and Predicts Disease Recurrence , 2011, PloS one.

[51]  Jason Li,et al.  Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. , 2014, Cancer discovery.

[52]  Stephen C. J. Parker,et al.  Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma , 2013, Proceedings of the National Academy of Sciences.

[53]  Kun Qu,et al.  BRAFV600E remodels the melanocyte transcriptome and induces BANCR to regulate melanoma cell migration. , 2012, Genome research.

[54]  Zhongming Zhao,et al.  Snowball: resampling combined with distance-based regression to discover transcriptional consequences of a driver mutation , 2015, Bioinform..

[55]  J. Utikal,et al.  Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.

[56]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.

[57]  Damien Kee,et al.  Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. , 2010, Cancer cell.

[58]  J. Borlak,et al.  Cross-talk between Aryl Hydrocarbon Receptor and Mitogen-Activated Protein Kinase Signaling Pathway in Liver Cancer through c-raf Transcriptional Regulation , 2008, Molecular Cancer Research.